GlaxoSmithKline has agreed to sell a portfolio of international OTC brands, excluding the troubled anti-obesity drug alli® (orlistat, 60 mg), to South Africa’s Aspen Pharmacare for £164 M (US$263 M). The divested brands generated sales of approximately £60 M (US$94 M) in 2011. The acquisition will drive growth for Aspen in Latin America and Southeast Asia.